Profile data is unavailable for this security.
About the company
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. It has a diversified business, commercializing products across eight core species: dogs, cats and horses (companion animals) and cattle, swine, poultry, fish and sheep (livestock); and within seven major product categories: parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics and medicated feed additives. The Company operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.
- Revenue in USD (TTM)8.54bn
- Net income in USD2.34bn
- Incorporated2012
- Employees14.10k
- LocationZoetis Inc10 Sylvan WayPARSIPPANY 07054United StatesUSA
- Phone+1 (973) 822-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.zoetis.com/
Mergers & acquisitions
Acquired company | ZTS:NYQ since announced | Transaction value |
---|---|---|
Adivo GmbH | -7.40% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Moderna Inc | 6.85bn | -4.71bn | 40.80bn | 5.60k | -- | 2.94 | -- | 5.96 | -12.39 | -12.39 | 17.68 | 36.27 | 0.3093 | 8.15 | 6.01 | 1,222,857.00 | -21.29 | 20.95 | -25.94 | 29.51 | 31.47 | -- | -68.84 | 32.10 | 3.36 | -- | 0.0399 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
Iqvia Holdings Inc | 14.98bn | 1.36bn | 45.90bn | 87.00k | 34.65 | 7.51 | 18.49 | 3.06 | 7.30 | 7.30 | 80.42 | 33.67 | 0.5761 | -- | 4.76 | 172,229.90 | 5.22 | 3.24 | 6.80 | 4.07 | 34.96 | 34.32 | 9.06 | 6.03 | -- | 3.24 | 0.6911 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
Zoetis Inc | 8.54bn | 2.34bn | 77.48bn | 14.10k | 33.37 | 15.52 | 27.37 | 9.07 | 5.07 | 5.07 | 18.48 | 10.90 | 0.585 | 1.03 | 6.78 | 605,957.40 | 16.02 | 14.47 | 19.37 | 17.18 | 70.47 | 69.80 | 27.39 | 25.77 | 2.00 | 17.15 | 0.5682 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
Gilead Sciences, Inc. | 27.12bn | 5.66bn | 91.25bn | 18.00k | 16.26 | 4.00 | 10.99 | 3.37 | 4.50 | 4.50 | 21.56 | 18.33 | 0.4328 | 3.95 | 5.75 | 1,506,445.00 | 8.96 | 6.74 | 10.91 | 8.12 | 76.04 | 78.64 | 20.69 | 16.95 | 1.27 | 7.63 | 0.5234 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
Regeneron Pharmaceuticals Inc | 13.12bn | 3.95bn | 105.64bn | 13.45k | 27.69 | 4.05 | 24.15 | 8.05 | 34.76 | 34.76 | 115.32 | 237.41 | 0.4211 | 0.7289 | 2.39 | 975,256.50 | 12.69 | 20.18 | 14.19 | 23.22 | 86.16 | 86.63 | 30.14 | 38.11 | 4.94 | -- | 0.0943 | -- | 7.76 | 14.34 | -8.87 | 10.72 | 19.32 | -- |
Vertex Pharmaceuticals Incorporated | 9.87bn | 3.62bn | 107.98bn | 5.40k | 30.09 | 6.13 | 28.41 | 10.94 | 13.89 | 13.89 | 37.88 | 68.22 | 0.4828 | 2.10 | 6.57 | 1,827,630.00 | 17.71 | 19.92 | 20.93 | 23.64 | 87.21 | 87.67 | 36.68 | 35.85 | 3.78 | -- | 0.021 | 0.00 | 10.51 | 26.49 | 8.96 | 46.50 | 22.02 | -- |
Bristol-Myers Squibb Co | 45.01bn | 8.03bn | 109.66bn | 34.10k | 14.06 | 3.72 | 6.16 | 2.44 | 3.86 | 3.86 | 21.66 | 14.56 | 0.4689 | 4.24 | 5.01 | 1,319,824.00 | 8.38 | 3.05 | 10.89 | 3.76 | 76.44 | 76.13 | 17.86 | 7.69 | 1.31 | 12.39 | 0.5743 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 38.35m | 8.38% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 22.37m | 4.89% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 19.32m | 4.22% |
State Farm Investment Management Corp.as of 31 Dec 2023 | 16.34m | 3.57% |
Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 14.68m | 3.21% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 13.08m | 2.86% |
AllianceBernstein LPas of 31 Dec 2023 | 12.57m | 2.75% |
Geode Capital Management LLCas of 31 Dec 2023 | 9.84m | 2.15% |
Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 9.06m | 1.98% |
Wellington Management Co. LLPas of 31 Dec 2023 | 9.02m | 1.97% |